25 May 2013
Keywords: immunomedics, cea, -scan, following, 208-patient, phase, iii
Article | 05 June 1995
- Following a 208-patient US Phase III study, Immunomedics has
announced that its diagnostic imaging agent, CEA-Scan (Tc-labelled Fab
fragment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
24 May 2013
© 2013 thepharmaletter.com